CyFlow CD255 PE
| 品番 | AS153004 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu CD255 PE,CARL-1 | ||
| 包装単位 | 100 tests | ||
| 濃度 | - | ||
| 容量 | 1 ml | ||
| 関連製品 (アイソタイプコントロール) |
- | ||
| 反応性|交差吸着 | Human | レーザー | Blue, Green, Yellow |
| 抗原 | CD255, TWEAK | 最大蛍光波長 | 576 nm |
| クローン | CARL-1 | 最大励起波長 | 496 nm, 565 nm |
| ホスト | Mouse | 標識/Format | PE |
| アイソタイプ | IgG3 | 研究分野 | Immunophenotyping | Apoptosis |
| クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD255 PE,CARL-1
特異性
The mouse monoclonal antibody CARL-1 recognizes CD255 (TWEAK) antigen, a type II transmembrane protein of the TNF superfamily able to weakly induce apoptosis in many cell types.
抗原情報
CD255 (TWEAK; TNF-related weak inducer of apoptosis), a type II transmembrane protein expressed as membrane-bound and secreted form, can induce apoptosis in many tissues and cell lines through its receptor CD266 (TWEAK R). On the other hand, in endothelial cells this interaction can induce proliferation and promote angiogenesis including neovascularization of tumors. CD255 can act in a juxtacrine manner to initiate cellular responses, and induces secretion of pro-inflammatory cytokines. Besides CD266, CD255 may also bind to DR3.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Brown SA, Ghosh A, Winkles JA: Full‑length, membrane‑anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF‑kappaB pathway. J·Biol·Chem. 2010·Jun·4; 285(23):17432‑41. <·PMID:·20385556·>
• Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T: Proinflammatory effects of tumour necrosis factor‑like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin·Exp·Immunol. 2006·Dec; 146(3):540‑9. <·PMID:·17100776·>
• Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor‑inducible 14 mediates multiple pathways of TWEAK‑induced cell death. J·Immunol. 2003·Jan·1; 170(1):341‑8. <·PMID:·12496418·>
• Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H: Involvement of TWEAK in interferon gamma‑stimulated monocyte cytotoxicity. J·Exp·Med. 2000·Nov·6; 192(9):1373‑80. <·PMID:·11067885·>
• Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S: TWEAK induces NF‑kappaB2 p100 processing and long lasting NF‑kappaB activation. J·Biol·Chem. 2003·Sep·19; 278(38):36005‑12. <·PMID:·12840022·>
• Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp·Ther·Med. 2011·Jan; 2(1):103‑108. <·PMID:·22977477·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN